Company Brii Biosciences Limited

Equities

2137

KYG1645A1094

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Brii Biosciences Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Hong Kong S.E. Other stock markets 09:01:01 29/04/2024 am IST			5-day change	1st Jan Change
1.25 ^HKD	+7.76%		+23.76%	-45.18%

25/03	Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
22/03	Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.

Number of employees: 128

HKD in Million	2022	Weight	2023	Weight	Delta
Therapies for Infectious Diseases and Central Nervous System Diseases 100.0 %	60	100.0 %	1	100.0 %	-98.86%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	60	100.0 %	1	100.0 %	-98.86%

Managers	Title	Age	Since
Zhi Hong CEO	Chief Executive Officer	60	08/17/08
An Kang Li DFI	Director of Finance/CFO	47	01/20/01
David Margolis CTO	Chief Tech/Sci/R&D Officer	-	-
Yao Zhang CTO	Chief Tech/Sci/R&D Officer	-	-
Qing Zhu CTO	Chief Tech/Sci/R&D Officer	57	02/18/02
Eleanor de Groot CTO	Chief Tech/Sci/R&D Officer	55	15/22/15
Chris Fang IRC	Investor Relations Contact	-	-
Karen D. Neuendorff HRO	Human Resources Officer	49	27/22/27
Lisa Trivison Beck PRN	Corporate Officer/Principal	62	12/18/12
Jean-Luc Samuel Francois Girardet PRN	Corporate Officer/Principal	57	19/18/19

Members of the board	Title	Age	Since
Gregg Alton BRD	Director/Board Member	58	22/21/22
Tai Yin Yang BRD	Director/Board Member	70	01/22/01
Robert Nelsen BRD	Director/Board Member	60	22/18/22
Martin Murphy BRD	Director/Board Member	81	22/21/22
Yiu Wa Tsui BRD	Director/Board Member	74	22/21/22
Zhi Hong CEO	Chief Executive Officer	60	08/17/08
Hui Tang BRD	Director/Board Member	64	22/21/22
An Kang Li DFI	Director of Finance/CFO	47	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	729,639,166	587,398,431 ( 80.51 %)	0	80.51 %

Name	Equities	%	Valuation
Boyu Capital Advisory Co. Ltd. 9.871 %	72,019,612	9.871 %	8 M $
Shanghai Yunfeng Investment Management Co. Ltd. 4.943 %	36,069,510	4.943 %	4 M $
Hongshan 4.772 %	34,818,757	4.772 %	4 M $
Invesco Advisers, Inc. 4.626 %	33,751,238	4.626 %	4 M $
Zhi Hong 4.441 %	32,400,000	4.441 %	4 M $
Bosera Asset Management Co., Ltd. 0.7769 %	5,668,500	0.7769 %	659 076 $
UBS Asset Management (Hong Kong) Ltd. 0.6220 %	4,538,000	0.6220 %	527 633 $
An Kang Li 0.1261 %	920,082	0.1261 %	106 978 $
Xinyuan Asset Management Co., Ltd. 0.0956 %	697,500	0.0956 %	81 098 $
Hwabao WP Fund Management Co., Ltd. 0.008497 %	62,000	0.008497 %	7 209 $

Brii Biosciences Ltd. (China)

Zhongguancun Dongsheng, Building 7 1 North Yongtaizhuang Road

100192, Haidian

http://www.briibio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.074 CNY

Average target price

4.303 CNY

Spread / Average Target

+300.73%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BRII BIOSCIENCES LIMITED	-45.18%	108M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs